Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk, will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at risk of developing Alzheimer’s dementia.

Mature couple sitting doing a crossword

The Impact of Semaglutide in Amyloid Positivity (ISAP) trial will recruit 88 volunteers currently living without dementia from five UK clinical sites in: Oxford, Imperial College London, University College London, Exeter, and Bristol. Participants will have a PET (Positron emission tomography) head scan to check levels of amyloid protein in their brains. Scientists believe that higher levels of this protein are linked to an increased future risk of dementia. This new study is at the forefront of research that tests the concept that the long ‘preclinical’ stage of dementia, that is, the 10-20 years period during which the condition develops, but people do not have symptoms, is a window of opportunity to interfere with the disease process and delay or even prevent dementia.

Trial participants who have high amyloid protein levels in their brains will have further PET head scans to determine levels of the protein. These scans will check also for tau protein, which is thought to damage nerves, and to estimate levels of inflammation in the brain. Volunteers will then be asked to take either semaglutide, a drug used currently for type 2 diabetes, or a placebo tablet, every day for one year. Researchers will repeat the tau and inflammation scans to see if those taking the semaglutide drug have lower levels of tau protein and inflammation in their brains compared with people taking placebo.

Dr Ivan Koychev, ISAP Chief Investigator and Trial Steering Committee Co-Chair, Department of Psychiatry, University of Oxford, said:

 

The ISAP study uses a type of drug prescribed for diabetes, and for which there already are data suggesting that it is linked to a lower risk of dementia. We will test if it interferes in the preclinical and very early symptomatic stages with the underlying mechanisms driving Alzheimer’s disease – tau protein accumulation and neuroinflammation. The obvious advantage of exploring compounds already in clinical practice is that we cut years from drug development as their safety has already been tested. This innovative study builds on the existing collaboration between the University of Oxford and Novo Nordisk, as well as the Oxford-based Dementias Platform UK project and the Oxford Health Biomedical Research Centre, which aim to accelerate research into stopping dementia before it causes symptoms.’ 

Emeritus Professor Rury Holman, Co-Chair of the Trial Steering Committee, Diabetes Trials Unit, OCDEM, University of Oxford, said:

 

Developing an effective disease modifying therapy for Alzheimer’s disease remains one of the key unmet needs of modern medicine given the increasing numbers of people developing this condition and the associated disability, societal costs, and reduced life expectancy. ISAP is another great example of academia and industry working together for the benefit of patients.’

 

This research is sponsored by the University of Oxford, and funded through the company Novo Nordisk.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Engagement with arts and culture can have a positive impact on mental health in young people

A new study finds that engaging with arts and culture online can improve mental health in young people.

Increased Risk of Some Neurological and Psychiatric Disorders Remains 2 Years After COVID-19 Infection

New study from the University of Oxford and the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre investigated neurological and psychiatric diagnoses in over 1.25 million people following diagnosed COVID-19 infection, using data from the US-based TriNetX electronic health record network.

Tackling Suicide Risk in People With Mental Disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Alcohol affects the Human Biological Clock

The short-term effects of excessive drinking are well known, but to date it has been less certain whether alcohol also accelerates the aging process.

New Meta-Analysis Highlights No Antidepressant Effect of Statins Administered in Monotherapy

This new systematic review and meta-analysis of randomised controlled trials assesses the effects of statins given alone, without concomitant antidepressant treatment, in people with depressive symptoms, but who do not have a formal diagnosis of a depressive disorder.